.png)
Podcast with MedAsian
China healthcare policy landscape
Episodes
13 episodes
Section 1260H decoded: How Chinese biotech builds trust in the U.S.
Section 1260H & WuXi AppTec1260H is a policy signaling tool, not a sanction – identifies companies linked to China's military-civil fusionCreates indirect but real consequences: investor scrutiny, partner...
.png)
Beyond the Deal: How Chinese Healthcare Companies Can Build Long-Term Success in the U.S.
Evolution of globalization: Chinese healthcare companies have moved from transactional exports and licensing to becoming globally integrated players—pursuing co-development, overseas manufacturing, acquisitions, and ecosystem partnerships....
Views on the Trump visit to Beijing and outlook on US-China Bilateral relationship
The Trump visit tested the political will to stabilize U.S.-China relations and prevent uncontrolled escalation amid deep strategic competition, supply chain restructuring, and technology restrictions.Rather than a full reset, it signal...
Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part II)
National strategy: China has elevated AI healthcare into a broader national agenda, linking it to economic modernization, tech leadership, and solving structural pressures like an aging population and uneven medical access.Multi-a...
Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part I)
Surge drivers: Advances in deep learning and large language models, mounting pressure from aging populations and rising costs, plus heavy investment and government backing are converging to make AI a practical, system-shaping force in heal...
From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map (Part 2)
For multinational pharma in China: A strategic trade-off emerges between US market access and global efficiency. High tariffs penalize offshore production, pushing firms from “China for Global” to “China for China” models. Expect more US-b...
From Steel to Stem Cells: How a 1962 Cold War Trade Law Is Quietly Redrawing the Global Pharma Map
What is Section 232? A U.S. trade law allowing the President to restrict imports deemed a threat to "national security." It is now being applied to pharmaceuticals, reframing medicine as a strategic asset rather than just a commerci...
Policy advocacy, government relations, and bilateral investment opportunities in an evolving US-China landscape (Part 2)
A quick summary of this episode.US-China relations: Managed competition with selective decoupling, not full decoupling. Upcoming Trump visit expected to be transactional, not a dramatic reset.Bilateral investment<...
Policy advocacy, government relations, and bilateral investment opportunities
In this MedAsian podcast episode, Director of Government Affairs Felix Li shares insights from a two-week trip to Washington, D.C., outlining the evolving US-China landscape and what it means for multinational businesses.Selectiv...
2026 "Two Sessions" policy outlook and government affairs actions in a dynamic business environment
The quick summary of this episode of Podcast with MedAsian.New 5-Year Plan & Shift to Quality: 2026 marks the start of China’s 15th Five-Year Plan, with a moderate 4.5–5% GDP target that prioritizes quality over speed<...
Human-led vs. AI-led communications: APAC in action
The Core Conflict: In APAC, culture remains the superpower. AI can process data, but it cannot read a room, navigate hierarchy, or sense unspoken political tension.Key Takeaway:"AI informs speed. Human judgment protects authorit...